51 related articles for article (PubMed ID: 7593136)
1. The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.
Nagai Y; Ambinder AJ
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509198
[TBL] [Abstract][Full Text] [Related]
2. Treatment for relapsed acute promyelocytic leukemia.
Yanada M
Ann Hematol; 2022 Dec; 101(12):2575-2582. PubMed ID: 35972562
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Study of IRX195183, a RARĪ±-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.
Ambinder AJ; Norsworthy K; Hernandez D; Palau L; Paun B; Duffield A; Chandraratna R; Sanders M; Varadhan R; Jones RJ; Douglas Smith B; Ghiaur G
Front Oncol; 2020; 10():587062. PubMed ID: 33194741
[TBL] [Abstract][Full Text] [Related]
4. Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature.
Takeshita A; Asou N; Atsuta Y; Furumaki H; Sakura T; Ueda Y; Sawa M; Dobashi N; Taniguchi Y; Suzuki R; Nakagawa M; Tamaki S; Hagihara M; Fujimaki K; Minamiguchi H; Fujita H; Yanada M; Maeda Y; Usui N; Kobayashi Y; Kiyoi H; Ohtake S; Matsumura I; Naoe T; Miyazaki Y; Group TJALS
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32492981
[TBL] [Abstract][Full Text] [Related]
5. Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.
Abdel-Azim H; Sun W; Wu L
Pharmacol Ther; 2019 Dec; 204():107403. PubMed ID: 31470030
[TBL] [Abstract][Full Text] [Related]
6. Current first- and second-line treatment options in acute promyelocytic leukemia.
Massaro F; Molica M; Breccia M
Int J Hematol Oncol; 2016 Nov; 5(3):105-118. PubMed ID: 30302210
[TBL] [Abstract][Full Text] [Related]
7. Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report.
Kojima M; Ogiya D; Ichiki A; Hara R; Amaki J; Kawai H; Numata H; Sato A; Miyamoto M; Suzuki R; Machida S; Matsushita H; Ogawa Y; Kawada H; Ando K
Leuk Res Rep; 2016; 5():11-3. PubMed ID: 27144119
[TBL] [Abstract][Full Text] [Related]
8. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
9. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Coombs CC; Tavakkoli M; Tallman MS
Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
11. Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.
Ding W; Shimada H; Li L; Mittal R; Zhang X; Shudo K; He Q; Prasadarao NV; Wu L
Blood; 2013 Feb; 121(6):996-1007. PubMed ID: 23243275
[TBL] [Abstract][Full Text] [Related]
12. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
13. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4.
Hashimoto Y; Kagechika H; Kawachi E; Fukasawa H; Saito G; Shudo K
Biol Pharm Bull; 1996 Oct; 19(10):1322-8. PubMed ID: 8913505
[TBL] [Abstract][Full Text] [Related]
15. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
Niitsu N; Higashihara M; Honma Y
Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid receptors: involvement in acute promyelocytic leukemia.
Agadir A; Cornic M; Gourmel B; Lefebvre P; Degos L; Chomienne C
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):263-74. PubMed ID: 7920173
[TBL] [Abstract][Full Text] [Related]
17. Cotylenin A--a plant growth regulator as a differentiation-inducing agent against myeloid leukemia.
Honma Y
Leuk Lymphoma; 2002 Jun; 43(6):1169-78. PubMed ID: 12152984
[TBL] [Abstract][Full Text] [Related]
18. Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4.
Hashimoto Y; Kagechika H; Kawachi E; Fukasawa H; Saito G; Shudo K
J Cancer Res Clin Oncol; 1995; 121(11):696-8. PubMed ID: 7593136
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
